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While a plethora of extracellular molecules exist that modulate
cellular functions via binding to membrane receptors inside the
cell, their actions are mediated by relatively few signalling
mechanisms. One of these is activation of phosphatidylinositol 3-
kinase (PI-3K), which results in the generation of a membrane-
restricted second messenger, polyphosphatidylinositides contain-
ing a 3«-phosphate. How these molecules transduced the effects
of agonists of PI-3K was unclear until the recent discovery that
several protein kinases become activated upon exposure to 3«-
phosphorylated inositol lipids. These enzymes include protein
kinase B (PKB)}AKT and PtdIns(3,4,5)P
$
-dependent kinases
1 and 2, the first two of which interact with 3«-phosphorylated
ORIGINS OF AKT
The AKR strain of mice exhibit a high incidence of leukaemias
and lymphomas from spontaneous thymoma [1]. A retrovirus
termed AKT8 was isolated from one of these lines derived from
a spontaneous thymoma. This virus was demonstrated to
uniquely transform only mink lung cells (CCL64) in culture,
while virus inoculated into newborn mice was shown to be
tumorigenic [2]. The non-viral DNA component transduced
from the mouse genome was subsequently identified, and two
human homologues, AKT1 and AKT2, cloned [3]. The location
of the human AKT locus was mapped to chromosome 14q32,
proximal to the immunoglobulin-heavy-chain locus [4], a region
frequently affected by translocations and inversions in human T-
cell leukaemia}lymphoma, mixed-lineage childhood leukaemia
and clonal T-cell proliferations in ataxia telangiectasia, sup-
porting a role for this oncogene in formation of a variety of
tumours [5]. Analysis of a panel of human tumours revealed a 20-
fold amplification of AKT1 in a primary gastric adenocarcinoma.
AKT2, on the other hand, was mapped to chromosome region
19q13.1-q13.2 and shown to be amplified and overexpressed in
several ovarian carcinoma and pancreatic cancer cell lines [6,7].
A recent large-scale study of AKT2 alterations in ovarian and
breast tumours revealed amplification in 12.1% ovarian and
2.8% breast carcinomas [8]. Furthermore, amplification of AKT2
was especially frequent in undifferentiated tumours, suggesting
that AKT2 alterations may be associated with tumour aggress-
iveness.
Abbreviations used: PI-3K, phosphatidylinositol 3-kinase ; PKB, protein kinase B; PKA, protein kinase A; PKC, protein kinase C; RAC-PK,
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phosphoinositides via pleckstrin homology domains. Once
targeted to the membrane by this motif, PKB becomes
phosphorylated at two residues, which relieves intermolecular
inhibition, allowing the activated complex to dissociate and
modify its targets. Identification of these substrates is the subject
of intensive research, since at least one must play a key role
in suppressing apoptosis, as demonstrated by expression of
activated alleles of PKB. The generation of effective trans-
dominant mutants, coupled with genetic analysis of the protein
kinase in simpler organisms, should help in elucidating out-
standing questions in the functions, targets and regulation of this
important mediator of PI-3K signalling.
CLONING OF PROTEIN KINASE B (c-Akt)
Some 15 years after the identification of the AKT8 retrovirus the
cellular homologue of v-Akt was cloned independently by several
groups and found to be a 57 kDa protein serine}threonine kinase
[9–11]. Different strategies were utilized in the identification of
this novel kinase : degenerate oligonucleotide-based PCR against
protein kinase catalytic domains [9] ; low-stringency library
screening with a cAMP-dependent kinase probe [10] and
sequencing of a human cDNA hybridizing with v-akt DNA [11].
The kinase shows most similarity to protein kinase A (PKA)
and protein kinase C (PKC) and has thus has been termed both
protein kinase B (PKB) [9] or Related to A- and C-kinase
(RAC-PK; [10]) as well as c-Akt [11]. The current nomenclature
for this kinase has not been clearly resolved, but the name RAC
is no longer used to avoid confusion with the small GTP-binding
protein p21rac [12]. Mammalian genomes contain three genes
encoding PKBs (termed a}AKT1, b}AKT2 and c) (see Figure
1). PKBb and PKBc are approx. 82% identical with the a-
isoform, although PKBc lacks 23 amino acids at the C-terminus
compared with the others [13]. Homologues have also been
identified in the nematode worm Caenorhabditis elegans and
the fruitfly Drosophila melanogaster, demonstrating wide
evolutionary conservation [14,15].
Sequence analysis of PKB}Akt and v-Akt cDNAs revealed
that the viral gene is a fusion between a truncated tripartite viral
group-specific antigen gag (p12, p15, Dp30) and PKB}AKT1
(Figure 1). These two domains are joined by a 21-amino-acid-
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Figure 1 Schematic representation of PKB structure
The domain structure and size of v-Akt, PKB isoforms (a, b and c) and Drosophila PKB (DPKB) are indicated. v-Akt consists of a fusion of PKB with a tripartite viral gag protein (pink) and is
myristoylated, targeting it to the membrane. The N-terminus of PKB contains a PH domain (‘ PH ’) and glycine-rich region (‘G ’). The C-terminus has a regulatory role (‘R ’) and shows similarity
to protein kinase C isoforms. The positions of activating phosphorylation sites in all PKB isoforms are indicated (see the text for details). It should be noted that PKBc lacks the most C-terminal
serine phosphorylation site, owing to truncation.
long peptide encoded by sequences from the 5«-untranslated
sequence of PKB}AKT1 plus three extra nucleotides at the
recombination breakpoint. This structure immediately suggests a
mechanism for oncogenic activation of PKB. The viral gag
protein is myristoylated at its N-terminus and normally targeted
to the plasma membrane. Indeed, while PKB is localized pri-
marily in the cytosol (90%), v-Akt is myristoylated and dispersed
among various cellular compartments, with 40% being localized
to the plasma membrane, 30% nuclear and 30% cytosolic [16].
This has dramatic consequences for regulation and function, as
discussed below. Analysis of the translated sequence of PKB
cDNA reveals a multi-domain protein. The N-terminus contains
an Src homology 2 (SH2)-like domain that has been subsequently
redefined as a pleckstrin homology (PH) domain [17,18]. The
central catalytic domain shows considerable similarity to PKA
and PKC, as mentioned above, while the C-terminal tail shows
similarity to a regulatory region present in members of the PKC
family [19]. How these various domains play a role in regulation
of kinase activity will be discussed in detail below.
PKB expression
PKBa and PKBb are widely expressed, with highest levels in
brain, thymus, heart and lung [9,10,19]. Expression of the c-
isoform is more restricted (high in brain and testes, lower in
heart, spleen, lung and skeletal muscle), but all tissues contain at
least one form of PKB. Little is currently known concerning
regulation of expression of PKB; however, it appears to be up-
regulated as cells become more terminally differentiated. For
example, PKB expression is low in a multipotent fibroblast cell
line (10T1}2), but is increased when these cells are transformed
with MyoD to induce differentiation into myocytes [20]. Fur-
thermore, differentiation of pluripotent P19 embryonal car-
cinoma (EC) cells with retinoic acid results in dramatic induction
of PKB after 3 days, while terminally differentiated derivatives of
P19 embryonal carcinoma cells (MES-1, END-2, EPI-7)
constitutively express high levels of PKB (P. J. Coffer, un-
published work). Finally, 3T3-L1 fibroblasts spontaneously
differentiate into adipocytes when transfected with a
constitutively active PKB [21,22]. Thus expression of PKB
appears to be tightly connected with the terminal differentiation
of various cell types. Drosophila PKB expression shows no
spatial restriction during embryogenesis, but is maternally as
well as zygotically expressed [15,23].
Phosphatidylinositol 3-kinase (PI-3K) mediates PKB activation
Despite the fact that PKB had oncogenic potential, its normal
regulation and function were, until recently, unclear. About 4
years after the kinase was cloned, several groups concurrently
identified PKB as a downstream target of PI-3K activation
[24–26]. PI-3K phosphorylates phosphoinositides (PtdIns) at the
3-position of the inositol ring, generating PtdIns3P, PtdIns(3,4)P
#
and PtdIns(3,4,5)P
$
. Studies were primarily based on two observ-
ations : (i) that growth-factor-induced PKB activation could be
completely blocked by addition of wortmannin, an inhibitor of
PI-3K, and (ii) that growth-factor-receptor point mutations that
prevent the activation of PI-3K also inhibit PKB. PKB was
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found to be rapidly and transiently activated by platelet-derived
growth factor (PDGF), epidermal growth factor (EGF), basic
fibroblast growth factor (bFGF) and insulin, and this activation
was paralleled by phosphorylation of the kinase itself [24,25].
Phosphorylation appears to be critical for kinase activity, as
treatment of active PKB immune complexes with phosphatase
abolishes the ability of the kinase to phosphorylate in itro
substrate [24,26,27] (see below). This phosphorylation can be
observed on SDS}PAGE as a slower migrating form of PKB in
much the same way as extracellular-signal-regulated mitogen-
activated protein kinases (ERK MAP kinases) p44ERK1}
p42ERK2. While the inhibitory effects of wortmannin on PKB
activation must be cautiously interpreted in view of potential
non-specific effects of this pharmacological reagent, using the
PDGF receptor as a paradigm, two tyrosine residues, Tyr(%! and
Tyr(&", were demonstrated to mediate PKB activation [24,25].
Phosphorylation of both these tyrosine residues generates high-
affinity binding sites for the p85 regulatory subunit of PI-3K [28].
Furthermore, co-transfection of a dominant-negative form of PI-
3K (Dp85; [29]) also inhibited PKB activation [24]. It was later
shown that introduction of constitutively active mutants of the
catalytic subunit of PI-3K was sufficient to activate PKB in cells
[30,31]. These studies strongly implicated PKB as a downstream
effector of growth-factor-stimulated PI-3K activation in a variety
of cell types. Subsequently PKB has been shown to be activated
by a wide variety of stimuli including haemopoietic cytokines [IL
(interleukin)-2, IL-3, IL-4, IL-5], chemokines [formylmethionyl-
leucylphenylalanine, IL-8, RANTES (regulated on activation,
normal T-cell expressed and secreted)], heat shock, hyperosmo-
larity, hypoxia, integrins, the T-cell antigen receptor and nerve
growth factor [32–40].
While activation of PI-3K appears to induce PKB universally,
the reverse does not hold. For example, heat-shock-mediated
activation of PKB is insensitive to inhibition by wortmannin in
some cell types [32]. Agents which raise intracellular cAMP levels
can also activate both PI-3K and PKB activity [38,39]. However,
it has been shown in 293 cells that pharmacological reagents that
elevate cAMP levels, such as forskolin, can activate PKB in a PI-
3K-independent manner [41]. PKB containing activating
mutations at the serine}threonine phosphorylation sites (see
below) is refractive to activation by elevated intracellular levels
of cAMP. Thus it was suggested that cAMP modulates the same
phosphorylation events that are stimulated by PI-3K-dependent
PKB-activating stimuli. In contradiction, however, insulin and
forskolin were observed to have synergistic effects on PKB
activation, suggesting alternative mechanisms [41]. Since most
physiological agonists that elevate cAMP levels also strongly
activate PI-3K, it is still unclear as to the relevance of these
observations. Finally, in rat epididymal fat cells, isoprenaline
(‘ isoproterenol ’) (acting through a
$
-adrenoreceptors), but not
cAMP analogues, increases the activity of PKB, although to a
lesser extent than insulin [42]. In this system wortmannin
abolishes PKB activation by insulin, but has no effect on the
activation seen in response to isoprenaline. Activation of PKB by
isoprenaline was not accompanied by an electrophoretic mobility
shift. Thus it appears that, while activation of PI-3K is the major
factor regulating activation of PKB, several alternative
mechanisms may exist that are utilized by specific stimuli.
Interestingly, activation of PKB can be down-regulated by
certain stress stimuli which increase intracellular ceramide [43,44].
Thus agents which activate acidic sphingomyelinase (such as
tumour necrosis factor-a) may antagonize PKB activity. The
level at which this occurs is presently unclear, but appears to be
between PI-3K and PKB. These data are of particular relevance
in light of the anti-apoptotic functions of PKB (see under ‘Anti-
apoptotic signalling mediated by PKB’ below) and may represent
a mechanism for cross-talk between survival and apoptotic
stimuli.
Mechanisms of activation of PKB
The finding that PKB activity is induced in a PI-3K-dependent
manner immediately suggested that the 3«-phosphorylated lipid
products of PI-3K mediated the activation. Indeed, incubation of
purified PKB with purified 3«-phosphorylated phospholipids
resulted in various extents of activation [45,46]. Others have
found binding in the absence of activation [47]. These lipids [such
as PtdIns(3,4)P
#
and PtdIns(3,4,5)P
$
] specifically associate with
PH domains in a number of proteins [48]. Since certain mutations
of the PH domain of PKB rendered it inactive, the mechanism of
activation of the protein kinase could simply occur via re-
cruitment to the plasma membrane following formation of 3«-
phosphorylated phosphatidylinositides. As mentioned above,
activation of PKB is accompanied by its phosphorylation. Since
dephosphorylation of the kinase causes its inactivation,
phosphorylation appears to be a required step in the induction
process. Phosphorylation could occur via transphosphorylation
by a protein kinase(s) acting on PKB or by autophosphoryl-
ation of PKB following its activation (a commonphenomenon for
protein kinases). The issue has been resolved by the identification
of two phosphorylation sites on PKBa and PKBb and the
identification of at least one protein kinase activity that targets
these sites [49] (see Scheme 1).
Upon stimulation of PI-3K activity, PKBa becomes
phosphorylated at two residues, Thr$!) within the P-loop of the
protein kinase domain and Ser%($. Mutagenesis of each residue to
alanine revealed that both are required for full activation [49].
Furthermore, substitution with aspartic acid residues rendered
PKB partially active and independent of agonists or inhibition
by PI-3K antagonists such as wortmannin. The phosphorylation
sites are conserved in PKBb (Thr$!*, Ser%(%), although, due to a
C-terminal truncation, PKBc lacks a Ser%($ homologue (PKBc
Thr$!& is in an analogous context to the P-loop site in PKBa) [50]
(see Figure 1).
PKB complexes
PKB exists as a multimer in cells. It has been demonstrated that
the PH domain of PKB mediates interaction between PKB
molecules, playing a role in regulation [51]. Transfection of COS-
1 cells with an epitope-tagged C-terminally truncated PKB allows
co-immunoprecipitation of full-length PKB. Deletion of the PH
domain on the epitope-tagged PKB abolishes this interaction.
Furthermore, the PH-domain interaction appears to be highly
specific, as determined by the failure of the PKBa PH domain to
bind to PKBb in transfected COS cells. Utilizing the yeast two-
hybrid system, it was further shown that this PH-domain-
dependent interaction required no further adaptor proteins.
Surprisingly, the addition of recombinant PKB PH-domain
protein to immune complex PKB kinase assays resulted in a
significant enhancement of kinase activity.
Bruton tyrosine kinase (Btk) has been reported to associate
with PKC family members through its PH domain, although the
role of this association is unknown [52]. Similarly, Kikkawa and
co-workers have shown that in itro PKB can associate with
PKCs, although with no measured effect on activity [53,54]. The
functional relevance of these observations in io remains to be
resolved.
Expression of an epitope-tagged kinase-defective mutant of
PKB is able to ‘fish out ’ endogenous PKB, since the mutant
associates with endogenous wild-type PKB (J. Jin, L. Ruel, B.
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Scheme 1 Model of mechanism of activation of PKB by growth factors
In resting cells PI-3K and PKB are cytoplasmic and inactive (via intermolecular inhibition of the protein kinase domain). Upon receptor tyrosine kinase (RTK) activation, the receptor autophosphorylates
on tyrosine residues, some of which form docking sites for SH2 domains within the regulatory subunit of PI-3K, recruiting it to its source of phosphoinositides in the membrane. Phosphorylation
of these lipids at the 3«-position of their inositol rings acts to recruit PH-domain-containing proteins such as PKB and the PDKs. The assembly of these proteins within the same microdomain
facilitates phosphorylation of PKB at the two activatory sites, which relieves the intermolecular inhibition. Activated PKB dissociates from the membrane and moves to the nucleus and other subcellular
compartments. Abbreviations : PIP2, PtdIns(4,5)P2 ; PIP3, PtdIns(3,4,5)P3.
Staveley, A. Manoukian and J. R. Woodgett, unpublished
work). Using this type of hybrid-association analysis we have
probed the composition of the multimer as well as the mechanism
of activation. Expression of epitope-tagged versions either ATP-
binding site (K179A) or T308A}S473}A mutants in cells results
in negligible kinase activity recoverable by anti-epitope immuno-
precipitation. Co-expression of either of these mutants with wild-
type PKB allows recovery of normally regulated PKB in the anti-
epitope immunoprecipitates. Surprisingly, the same is true when
the ATP-binding-site mutant and the activation-site mutants are
co-expressed (J. Jin, L. Ruel, B. Staveley, A. Manoukian and
J. R. Woodgett, unpublished work). That is, whereas the two
types of mutation independently incapacitate PKB, a complex
containing both regains activation potential. Our interpretation
of these data is that, in resting cells, the PKB multimer is held in
an inactive conformation via intermolecular interactions. Phos-
phorylation of the activatory phosphorylation sites on one
molecule releases the inhibitory effect on a partnering molecule.
Since the phosphorylation occurs via ‘ third party ’ kinases, the
PDKs (see under ‘PKB kinases ’), the phosphorylated PKB
molecule does not need intrinsic kinase activity to deregulate its
partner. Likewise, the partner does not actually require phos-
phorylation of its own sites (T308}S473) for activation; rather
phosphorylation must occur on the regulatory sites of the PKB
molecule that is inhibiting its activity. Phosphorylation essentially
causes intermolecular derepression of the PKB complex.
Phosphorylation at the activatory sites in the PKB complex is
both necessary and sufficient for activation. How then is the
oncogenic form, v-Akt, activated? Substitution of the two
phosphorylation sites with alanine inactivates the oncogenic,
gag-fused mutant, indicating that the oncogene is still dependent
on phosphorylation for activity. v-Akt is constitutively
phosphorylated at the two activatory phosphorylation sites,
suggesting that the increased membrane localization of this
mutant allows interaction with the T308}S473 kinases. Since v-
Akt activity is decreased by wortmannin treatment, these kinases
must be as dependent on the presence of 3«-phosphorylated
polyphosphoinositides as wild-type PKB.
PKB kinases
PDK1
The mutational analysis of T308 and S473, as well as their local
sequence context, suggested that the two sites were independently
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regulated [49]. In the case of PKBc, activation must only be
dependent upon the P-loop site, since the C-terminal regulatory
site is absent. An ATP-binding site}kinase-inactive PKB in cells
retained agonist-dependent phosphorylation of Thr$!) and Ser%($
when expressed, suggesting that autonomous kinase activities
were responsible for PKB phosphorylation at these sites. Using
glutathione S-transferase–PKB as an affinity column, Alessi et al.
purified a 67 kDa protein kinase from rabbit skeletal muscle [56].
This enzyme specifically phosphorylated Thr$!), partially acti-
vated PKB (30-fold) in itro and was dependent for activity on
PtdIns(3,4)P
#
and PtdIns(3,4,5)P
$
[54]. In view of its dependency
on these lipids, it was termed PtdIns(3,4,5)P
$
-dependent protein
kinase-1 (PDK1). A similar (perhaps identical) protein kinase to
PDK1 was partially purified from rat brain [57]. Cloning of
PDK1 revealed it to be ubiquitously expressed and, like PKB
itself, to contain a PH domain but, in this case, C-terminal to its
kinase domain [58,59]. Overexpression of PDK1 in cells was
sufficient to partially activate PKB and mutation of the PH
domain in either PKB or PDK1 significantly reduced activation
of PKB [58,60]. Interestingly, treatment of cells with agonists of
PI-3K did not result in changes in PDK1 activity or phos-
phorylation state, suggesting that it is constitutively active and
its function is instead regulated by subcellular localization.
Scanning of the gene databanks revealed PDK1 to be most
similar (54% identity within the kinase domain) to a Drosophila
protein kinase termed DSTPK61 [58]. This kinase can also
phosphorylate Thr$!) of PKB in a PtdIns(3,4,5)P
$
-dependent-
manner. DSTPK61 has been implicated in sexual differentiation
of Drosophila and in oogenesis and spermatogenesis. The
DSTPK61 gene undergoes sex-specific splicing, which yields
distinct 5«- and 3«-untranslated regions in male and female flies.
The role of this sex-specific regulation in PKB functions in
Drosophila is currently unclear, but may relate to differential
regulation of apoptosis (see below).
PDK2
What of the protein kinase that targets PKB at Ser%($
(operationally termed PDK2)? The phosphorylation status of
this residue is unaffected in cells overexpressing PDK1, indicating
that this residue is autonomously regulated and is not an
autophosphorylation site dependent on Thr$!) phosphorylation
[56]. In itro, the site can be phosphorylated by mitogen-activated
protein kinase-activated protein (MAPKAP) kinase-2, an enzyme
that is regulated by the p38 MAP kinase pathway [49]. How-
ever, MAPKAP kinase-2 is very unlikely to physiologically
phosphorylate Ser%($, since agents that induceMAPKAPkinase-2
activity, such as tumour necrosis factor-a and IL-1, do not
induce PKB activation (or Ser%($ phosphorylation; J. Jin and
J. R. Woodgett, unpublished work) and a variety of PKB
agonists, including insulin, insulin-like growth factor (IGF)-1
and PDGF do not significantly activate MAPKAP kinase-2. The
identity of the physiologically relevant Ser%($ kinase is currently
unknown, but it is likely to be regulated in an analogous manner
to PDK1, since phosphorylation of the two activatory sites on
PKB is usually co-ordinated. It is therefore tempting to specu-
late that PDK2 will contain a lipid-binding domain such as the
PH domain in PKB and PDK1.
Synopsis of the activation process
The following model of PKB activation is consistent with the
data generated to date (Scheme 1). In resting cells there are
detectable but low levels of PtdIns(3,4)P
#
and PtdIns(3,4,5)P
$
.
The levels are insufficient to allow recruitment of all of the
elements required for activation of the PKB multimer to the
plasma membrane. However, addition of membrane targeting
domains to PKB presumably stabilizes the protein kinase within
the correct proximity for interaction with the transiently as-
sociating PDK1 and PDK2 molecules that are attracted to the
membrane by the basal levels of polyphosphorylated PtdIns
molecules. Hence, the gag–PKB or membrane-targeted PKB
complexes slowly accumulate the necessary phosphorylation
events for its activation in the absence of a signal.
Growth-factor activation of wild-type PKB requires catalytic
activation of PI-3K via the association of SH2 domains on its
85 kDa regulatory subunit with specific phosphotyrosine residues
on activated receptors. This localizes the 110 kDa catalytic
domain to the plasma membrane, where it produces PtdIns(3,4)P
#
and PtdIns(3,4,5)P
$
. This ‘microdomain’ of PtdIns(3,4)P
#
and
PtdIns(3,4)P
$
would attract the two PDKs as well as the PKB
multimer to form an activatory complex, resulting in the
generation of biphosphorylated PKB complexes. The
phosphorylated activation sites de-repress the kinase activity of
the complex, and this form of the protein kinase is fully active
and independent of phospholipids (as revealed by the properties
of the double aspartate mutant). Immunofluorescence studies
have revealed that, following activation, transfected PKB concen-
trates in the nucleus ([61,62] ; J. Jin and A. Manoukian, un-
published work). Similar effects can be observed with endogenous
PKB using antibodies specific for the phosphorylated form of
Ser%($ in mammalian cells and Drosophila embryos (J. Jing, J. R.
Woodgett and A. Manoukian, unpublished work). The process
is reversed upon dephosphorylation of the two regulatory sites,
which causes intramolecular inhibition, rendering the enzyme
complex inactive until it is recycled to the membrane.
This model begs the question of why the mechanism is so
complicated? Since PKB contains a PH domain, why should it be
regulated as amultimeric complex by two additional PH- domain-
containing kinases? The data suggest that formation of multi-
protein activation structure at the membrane is requisite, and a
clue to the complexity issue may be gleaned from the membrane-
targeting mutants which are signal-independent. It would appear
that the basal concentrations of activatory phospholipids are too
high to guarantee that the enzyme is inactive under resting
conditions. By requiring the interaction of three different types of
molecules, the chances of all three simultaneously co-localizing
are substantially reduced. Still, it is not really clear why two
PDKs are necessary, especially since PKBc harbours only one
activation site. Perhaps Ser%($ acts as a ‘ turbo-charger ’ to create
a second tier of kinase activity. This would imply the existence of
two classes of activated PKB within a cell and may allow distinct
thresholds of responses depending on the strength of the
activatory signal. Further, depending on the proportion of PKB
molecules in a multimer, there will be differing degrees of
activation. For example, if the PKB complex is a trimer, one of
the molecules might be fully dephosphorylated and therefore
exerting an inhibitory effect. The trimeric model allows 64
possible phosphorylation states of the two activatory sites in a
complex, all but one (the fully dephosphorylated state) having
some level of activity, resulting in a smooth spectrum of possible
activity levels that will be acutely tuned to the original signal
intensity and rate of dephosphorylation of the sites.
It is possible that PKB represents only one target of the PDKs
and that other signalling molecules are regulated by these two
enzymes. In this scenario, the PDKs could be a processing
factory for the PI-3K pathway and modify the functions of
additional enzymes unrelated to PKB.
Another, as yet unresolved, question is whether membrane-
‘anchored’ PKB is functionally identical with activated wild-
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type protein. In the case of gag–PKB}v-Akt, which is oncogenic,
a significant fraction of the protein kinase is soluble. However,
other mutants, such as those with GTPase farnesylation
sequences such as the CAAX box, are physically restricted to the
membrane. Indeed, despite the fact that this mutant is
‘catalytically activated’, it acts as a dominant negative protein by
holding the endogenous PKBs to the membrane (presumably by
forming complexes with these molecules) [63]. Translocation of
the activated protein kinase to the nuclear compartment suggests
that its primary targets may exist there (see below), and while
plasma-membrane tethering may result in formation of active
PKB, its exclusion from soluble or nuclear targets would likely
restrict its biological activity. Conversely, the double aspartate
mutant, PKB
DD
, presumably never interacts with membranes (at
least in resting cells) and therefore will not encounter membrane-
localized substrates. Comparison of the biology and the sub-
strates targeted by PKB–CAAX and PKB
DD
with wild-type PKB
may provide insights into the critical substrates for particular
processes.
BIOLOGICAL FUNCTIONS OF PKB
Since PKB activity is stimulated by a variety of growth factors
and insulin, much effort has focused on the acute metabolic
effects associated with its activation (these targets are summarized
in Scheme 2). However, a role for the enzyme in protecting cells
from apoptosis has recently been defined in mammals and
Drosophila. The linkage between these functions remains to be
established.
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Scheme 2 Metabolic functions regulated by PKB
Metabolic functions of PKB (red) can be divided into those that regulate protein synthesis and those that regulate glycogenesis (pink). While a role for PKB has been implicated in many of these
processes, a direct link requires further confirmation (see the text for details). Protein synthesis : PKB-mediated phosphorylation of 4E-BP1 (PHAS-I) leads to its dissociation from eIF-4E, resulting
in eIF4F complex-formation and increased initiation of translation. Activation of p70S6K by PKB may also lead to increased translation of a specific subset of mRNAs, while inhibition of GSK-3
activity results in the dephosphorylation and activation of eIF2B, leading to increased peptide-chain initiation. Inhibition of eEF2 phosphorylation by rapamycin results in activation of overall peptide-
chain elongation. Glucose metabolism : phosphorylation of PFK2 mediated by PKB results in production of fructose 2,6-bisphosphate (Fru-2,6-P2) and activation of glycolysis, while inhibition of
GSK-3 results in increased glycogen synthesis by regulating glycogen synthase phosphorylation. Furthermore, activation of PKB can mediate the glucose uptake via translocation of GLUT4
transporters to the cell surface.
Tools for modulating PKB activity
Several approaches have been developed to assess the role of
PKB is various cellular processes. Most involve expression of
activated alleles or putative dominant negative mutants. While
constitutively active mutants exist, they are known to affect the
growth potential of cells or to induce differentiation. Currently
there are no pharmacological inhibitors of PKB, and attempts to
generate transdominant negative mutants have been irrepro-
ducible. One consequence of the intermolecular repression model
of regulation (see under ‘Mechanisms of activation of PKB’) is
that ATP-binding-site mutants or activation-site mutants retain
competency to either activate their partners in a complex or be
activated themselves respectively. Such mutants may reduce the
overall activation capacity of a PKB complex, but will be
incapable of full inhibition unless expressed at extremely high
levels. For inhibition to occur, mutants containing both ATP-
binding-site and activation-site substitutions would be required.
Overexpression of all of these mutants may interfere with other
PH-domain-containing proteins (of which there are in excess of
100, some of which are highly specific for 3-phosphorylated
phosphoinositides). If the PDKs are required for activating other
proteins, overexpression of PKB mutants might titre out not
only their PKB activation capacity but also other PDK-de-
pendent processes.
For these reasons, data using mutants of PKB should be
interpreted with caution and will likely require revisiting once
more effective and specific means of manipulating the activity
levels of the protein kinase are found. With these caveats in
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mind, there are several processes in which a role for PKB has
been implicated, including intermediary metabolism and protein
synthesis.
Metabolism
Glucose transport
One of the major metabolic responses invoked by insulin
challenge is the stimulation of glucose transport in muscle and
adipose tissue by recruiting glucose transporters (GLUT1 and
GLUT4) to the cell surface from intracellular pools. However,
the molecular mechanisms regulating this process remain ill-
defined. Inhibitors of PI-3K have been reported to block the
ability of insulin to stimulate glucose uptake [64–66], while
overexpression of active forms of PI-3K at least partially mimic
the effect of insulin [67–70]. Several groups have recently provided
a possible link between activation of PKB and the stimulation
of GLUT4 translocation [21,71,72]. As mentioned above,
expression of constitutively active membrane-targeted variants
of PKB in 3T3-L1 fibroblasts results in spontaneous differen-
tiation into adipocytes [21,22]. This may be due to the activation
of p70 S6-kinase (p70S'K), which has also been implicated in this
process [24,73]. Subcellular fractionation of 3T3-L1 adipocytes
reveals that GLUT4 is mostly located in the low- and high-
density microsomes [71]. The largest concentration of endogen-
ous PKB is found in the cytosol, while gag–PKB and the p85
subunit of PI-3K are enriched in membrane fractions. Fur-
thermore, constitutively active PKB induces glucose uptake
associated with increased GLUT1 expression and GLUT4 trans-
location to the plasma membrane [21,71]. The increased glucose
influx is associated with lipogenesis. Surprisingly, however,
insulin-stimulated glycogen synthesis is inhibited in the presence
of active PKB in 3T3-L1 adipocytes [21]. This inhibition of
insulin-stimulated glycogenesis may be explained in that persis-
tent activation of this pathway could result in desensitization.
Interestingly, PDGF, while able to activate PI-3K in 3T3-L1
adipocytes, is unable to stimulate GLUT4 translocation [74,75].
In these cells PDGF is also unable to induce phosphorylation of
PKB, although activity measurements were not performed [76].
Activation of PI-3K by PDGF occurs only in plasma mem-
branes, whereas insulin also induces activation in low-density
microsomes, where GLUT4 expression is predominant [75,76].
Furthermore, okadaic acid, a potent stimulator of GLUT4
transport, induces PKB phosphorylation as efficiently as insulin
without activation of PI-3K. These observations demonstrate a
parallel between the ability of agents to promote GLUT4
translocation and activate PKB, suggesting an important func-
tion for PKB in this process. These data further suggest that
compartmentalization may play a critical role in restricting
which agonists can activate PKB. Recently, insulin treatment of
3T3-LI adipocytes has been reported to increase the association
of PKBb with GLUT4-containing vesicles, suggesting that spe-
cific isoforms may play distinct roles and interact with different
substrates [77]. The distribution rather than the mere presence
of PI-3K and its lipid products, the protein kinase(s) upstream of
PKB and the PKBs themselves will thus regulate the outcome
of receptor stimulation.
Glycogen synthesis
Apart from regulation of glucose-transporter function, insulin
stimulation also results in the phosphorylation and inactivation
of glycogen synthase kinase-3 (GSK-3) and activation of glycogen
synthesis [78–80]. Work by Hemmings, Alessi and co-workers
has demonstrated that GSK-3 is a substrate of PKB, at least in
itro [81]. Treatment of L6 myoblasts with insulin results in a
40–50% inhibition of GSK-3, a process inhibited by PI-3K
inhibitors. PKB from insulin-treated L6 myotubes inactivated
GSK-3a and GSK-3b in itro, and this inhibition was reversed by
the serine}threonine-specific protein phosphatase PP2A1. Fol-
lowing insulin treatment, the two isoforms of GSK-3 become
phosphorylated at Ser#$ and Ser* respectively. Using a synthetic
peptide based around the latter residue, Cross et al. identified the
major Ser* kinase in skeletal-muscle extracts as PKB [81]. In
support of this, overexpression of PKB in cells reduced GSK-3
activity by a phosphorylation-dependent mechanism. These data
would predict that insulin enhancement of glycogen synthesis in
adipocytes should be regulated by PKB. However, as mentioned
above, constitutively active PKB mutants did not increase the
rate of glycogen synthesis in transfected 3T3-L1 adipocytes [27].
An explanation for this inconsistency has been recently proffered
by work of Kadowaki and co-workers [82]. In 3T3-L1 adipocytes,
expression of gag–PKB did not affect either basal or insulin-
stimulated glycogen synthase activity, while wortmannin resulted
in complete inhibition of insulin-induced glycogen synthase
activity. In contrast, expression of gag–PKB in L6 myocytes
revealed an enhanced basal level of glycogen synthase activity
essentially comparable with that normally induced by insulin
stimulation. This demonstrates a distinct difference between the
mechanisms of glycogen synthesis in these two cell types. Indeed,
GSK-3 is expressed in L6 myocytes, but not 3T3-L1 adipocytes
[83], correlating with the ability of PKB to induce glycogen
synthesis only in L6 myocytes. Further work has suggested that
insulin activation of glycogen synthase in 3T3-LI adipocytes
occurs by at least two distinct mechanisms (including inhibition
of GSK-3 and activation of a phosphatase) which are temporally
regulated during adipogenesis [84].
Glycolysis
6-Phosphofructose 2-kinase (PFK2) is responsible for generating
fructose 2,6-bisphosphate, a key allosteric activator of 6-
phosphofructose-1-kinase, the rate-limiting enzyme in mam-
malian glycolysis. Phosphorylation of PFK2 by insulin, for
example, results in enhanced activation. It has been shown that
p70S'K, MAPKAP kinase-1 and PKB can all phosphorylate and
activate PFK2 in itro [85]. However, activation in isolated rat
cardiomyocytes by insulin is sensitive to wortmannin, but not to
rapamycin or PD098059, suggesting that a PI-3K-mediated
pathway is the major one [86]. Thus phosphorylation of PFK2
by PKB may explain how glycolysis is stimulated by insulin.
Protein synthesis
The stimulation of protein synthesis is another important re-
sponse to insulin observed in a variety of cell types, but
predominantly in skeletal muscle and adipose tissue [87]. A
critical event is the phosphorylation of 4E-binding protein [4E-
BP1; PHAS (pH- and acid-stable)-I] and its dissociation from
eukaryotic initiation factor 4E, leading to mRNA translation.
This phosphorylation occurs at multiple residues and appears to
involve PI-3K and p70S'K, since it is wortmannin- and rapamycin-
sensitive [88–90]. Since PKB activation is also wortmannin-
sensitive and can contribute to p70S'K activation [24], it may play
a role in the regulation of insulin-mediated protein synthesis.
Indeed expression of gag–PKB in 3T3-L1 or L6 cells results in a
much higher phosphorylation of 4E-BP1 even after treatment
with wortmannin [82,91]. Furthermore, this resulted in an
increase in the rate of protein synthesis in both basal and insulin-
treated cells. Thus, through combined activation of p70S'K,
causing ribosomal phosphorylation and increased translation,
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Scheme 3 Anti-apoptotic signalling mediated by PKB
Regulation of programmed cell death is critical in the control of development and homoeostasis of multicellular organisms. PKB (red) has been recently implicated as a critical component of anti-
apoptotic signalling through overexpression of various mutant constructs (see the text for details). Phosphorylation of Bad directly by PKB results in its dissociation from Bcl-2 and association
with 14-3-3 proteins. Expression of catalytically active PKB mutants promotes the expression of Bcl-2 and c-Myc, possibly through enhanced E2F trans-activation. The inhibition of ICE-like proteases
(caspases) also results in cellular protection. Inhibition of GSK-3 by PKB regulates adenomatous polyposis coli and b-catenin, which modulates cell adhesion, providing a potential link with anoikis.
Abbreviation : APC, adenomatous polyposis coli.
and phosphorylation of 4E-BP1 (either directly or indirectly),
PKB may induce increased rates of protein synthesis.
The situation is likely to be more complicated, however, since
PDK1 has recently been shown to be capable of inducing p70S'K
activation independently of PKB [92,93]. Thus PI-3K-mediated
p70S'K activation may well occur via alternative pathways. In
support of this, certain agonists can differentially induce PKB
and p70S'K [94].
3T3-L1 adipocytes expressing constitutively active myristoyl-
ated PKB exhibited a greater-than-20-fold increase in leptin
levels [95]. The induction appears to be due to a non-
transcriptional mechanism, since levels of mRNA in these cells
remain unchanged. Leptin is an adipostatic hormone playing a
role in energy balance, and its expression is regulated by insulin.
It is tempting to speculate that control of leptin protein synthesis
is indeed regulated in adipocytes by the mechanisms outlined
above.
Anti-apoptotic signalling mediated by PKB
Cell-survival pathways
Programmed cell death or apoptosis is fundamental in the
regulation of development and the control of tissue homoeostasis
under conditions of cellular stress [96]. While addition of growth
factors and cytokines to cells tends to promote mitogenesis, the
removal of these survival factors can result in the induction of
programmed cell death. Until recently the molecular mechanisms
of induction of apoptosis have remained unclear. However, work
utilizing inhibitors of PI-3K has implicated this signalling
pathway in regulating the balance between mitogenesis and
apoptosis [97–100]. These studies have led to the investigation of
the role of PKB in the regulation of both these processes in a
variety of cell systems.
Initial studies focused on the mechanism by which growth
factors promote the survival of cerebellar neurons [101]. Addition
of survival factors such as IGF-1 provide a signal that inhibits
apoptosis of neurons independently of p21ras-ERK activation
[101]. IGF-1 also stimulates PI-3K, and inhibition of the lipid
kinase utilizing the specific inhibitor LY294002 blocks neuronal
survival. Transfection of catalytically inactive PKB or the PH
domain of PKB alone into cerebellar neurons resulted in
increased apoptosis, and this could not be rescued by addition of
survival factors. Furthermore, overexpression of wild-type PKB
enhanced survival of neurons, and this was not inhibited by
LY294002. A protective role for the protein kinase in primary
neuronal cultures and in neuronal differentiation has also been
demonstrated [102–104].
Further studies have revealed that this model applies to a
variety of cell systems. In mesenchymal cells, induction of
apoptosis by c-Myc is effectively suppressed by PDGF and IGF-
1 [105], while survival is also inhibited by preincubation of cells
with LY294002 [106]. In Rat-1 fibroblasts, overexpression of a
constitutively active mutant of PI-3K delayed the onset of
apoptosis while, surprisingly, an oncogenic mutant of p21ras
(V12) resulted in both enhanced apoptosis and an increase in PI-
3K activity [107]. This suggests that p21ras triggers both a pro-
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apoptotic and PI-3K-dependent anti-apoptotic pathway. The
suggestion is that, in the absence of additional factors, the pro-
apoptotic pathway will dominate. The use of p21ras partial-loss-
of-function mutants has allowed further dissection of the role of
specific signalling pathways downstream of p21ras. These
mutants, in the context of an active p21ras(V12) background,
activate either the MAP kinase or PI-3K downstream signalling
pathways. Expression of p21ras(V12-C40), which activates only
PI-3K and not MAP kinase, induced PKB activity and was
effective in protecting cells against c-Myc-induced death after
serum withdrawal. Furthermore, p21ras(V12-S35), which is a
potent activator of MAP kinase, but not PI-3K, induced
apoptosis in overexpressing cells and did not activate PKB. The
expression of gag–PKB, a membrane-targeted constitutively
active mutant similar to v-Akt, resulted in substantial apoptotic
protection. In contrast with the work of Dudek et al. [101], the
overexpression of wild-type PKB alone did not effect the level of
apoptosis. The contradictory nature of p21ras in both inhibition
and induction of apoptosis is potentially regulated downstream,
depending on cell type and environment to generate the correct
response in the appropriate circumstance, analogous to c-Myc
itself. Irradiation of Rat-1 cells with UV-B also induces apoptosis
that is protected by either IGF-1 or introduction of constitutively
active mutants of either PI-3K or PKB [108].
Cytokine-mediated survival
PKB has also been demonstrated to play a role in cytokine-
mediated cell survival. Addition of IL-3 to 32D cells results in the
rapid induction of PKB activity, while mutants of PKB interfere
with IL-3-dependent proliferation [37]. Overexpression of wild-
type PKB protects 32D cells from apoptosis induced by IL-3
withdrawal. This appears also to be true not only for cell lines,
but also in primary human leucocytes, where PKB is rapidly
activated by survival factors [39] and rescue from cytokine-
depletion-mediated apoptosis is sensitive to wortmannin (P. J.
Coffer, unpublished work).
IL-2 controls T-cell survival, clonal expansion and induces
progression of T-cells through G1 into S-phase of the cell cycle.
IL-2 has also been demonstrated to activate PKB via PI-3K, and
this results in membrane translocation of PKB [33,36]. Activation
of PKB appears to be responsible for the activation of p70S'K in
T-cells via a pathway possibly involving the FRAP kinase [36].
Through the induction of Bcl-2, IL-2 inhibits apoptosis, and
through the combination of Bcl-2 and c-Myc it stimulates
progression through the cell cycle. Expression of catalytically
active PKB mutants in the pre-B-cell line BAF}3, containing an
IL-2 receptor defective in PI-3K activation, results in expression
of Bcl-2 and c-Myc and inhibition of apoptosis [33]. Thus
activation of PKB by IL-2 is responsible for the rescue from
apoptosis and activation of cell cycle progression.
Although the mechanisms by which PKB contributes to
regulation of apoptosis have become better defined (see below;
summarized in Scheme 3), relatively little is known concerning its
role in the regulation of cell-cycle progression. One recent study
has demonstrated that the cell-cycle regulator E2F is a component
of the downstream proliferative machinery regulated by PKB
[109]. One of the key events in G1-phase is the activation of E2F,
which in turn then binds to promoters and trans-activates various
genes critical for cell-cycle progression, such as cyclin. Brennan
et al. have shown that dominant-negative PI-3K and pharma-
cological inhibitors of PI-3K both abrogate IL-2 induction of
E2F almost completely [109]. Furthermore, expression of gag–
PKB also induced a strong transcriptional activation of E2F,
suggesting that these proliferation effects are indeed mediated via
PKB. However, constitutively active PI-3K was sufficient to
induce transcriptional activity of E2F, but was not sufficient
to induce DNA synthesis and G1-phase}S-phase transition in
Kit255 cells. Thus IL-2-induced DNA synthesis requires the
integration of a network of signals that include the activation of
PKB.
How does PKB protect cells?
Apoptosis requires the regulation of positive signals such as the
induction of the apoptosis inhibitor Bcl-2 and negative signals
such as the induction of interleukin-1-converting-enzyme (ICE)-
like protease (caspase) activity. Studies in fibroblasts have
demonstrated that PKB does not induce the Bcl-2}Bcl-X
L
, but
does inhibit the Ced3}ICE-like proteases that specifically cleave
the poly(ADP-ribose) polymerase, thus promoting survival [110]
(Scheme 3). A similar, but varying, observation was made in the
lymphoid cell line BAF}3 transfected with the IL-2 receptor [33].
Expression of catalytically active mutants of PKB promoted the
expression of Bcl-2 and c-Myc and inhibited apoptosis induced
by cytokine deprival.
Bcl-2 interacts with several partners as well as itself. The
ability to protect cells from activation of the caspase machinery
is critically dependent upon the ratio of anti-apoptotic Bcl-2 like
factors (Bcl-2, Bcl-X
L
, Mcl-1 and Bag) to pro-apoptotic factors
(such as Bcl-X
S
, Bax, Bad and Bak). These latter proteins can
stifle the protective effects of the Bcl-2 factors by dimerizing with
them. One of these, Bad, is regulated by phosphorylation at two
serine residues (Ser""# and Ser"$') [111,112]. Certain haemopoietic
cell lines that are dependent upon IL-3 as a survival factor induce
phosphorylation of Bad at the two serine residues when treated
with IL-3. Phosphorylation of Bad is accompanied by association
of the protein with 14-3-3 proteinswhich recognize phosphoserine
in the context of specific amino acid sequences [113]. Under these
circumstances Bad phosphorylation correlates with survival, and
agents that induce modification of Ser""# and Ser"$' should
provide a survival signal.
The first protein kinase reported to phosphorylate Bad at the
protective sites was c-Raf, although this kinase additionally
phosphorylates other residues on Bad [114]. Several groups have
since shown that Ser"$' can be specifically phosphorylated by
PKB in itro and in transfected cells [115–117]. With the use of
ion-exchange chromatography, PKB was found to be the major
Ser"$' kinase in PDGF-treated fibroblasts, although other protein
kinases, such as calmodulin-dependent protein kinase-II and
p90RSK, can also phosphorylate Ser"$' in itro.
Is phosphorylation of Bad the mechanism by which PKB
mediates its protective effect on cells? While this event may play
an important role in the survival signalling process, it is likely
that there are other contributing factors. For example, Bad
expression is rather restricted, and the other pro-apoptotic
members related to Bad (of broader tissue expression) have yet
to be shown to be regulated by phosphorylation (or PKB). In
addition, PKB activation and Badphosphorylation do not always
correlate in haemopoietic cell lines [118]. For example,
granulocyte–macrophage-colony stimulating factor stimulates
Bad phosphorylation even when PKB activation is blocked. IL-
4 actives PKB and promotes cell survival, but does not induce
Bad phosphorylation. As mentioned above, following activation,
PKB largely translocates to the nucleus, whereas the Bcl-2 family
of proteins are usually cytoplasmic or associated with the
mitochondria. While this will not prevent interaction between
activated PKB and Bad, it does suggest there are other primary
targets within the nucleus, possibly transcription factors that
mediate transcriptional induction of other survival genes. Fur-
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thermore, the physiological relevance of Bad phosphorylation by
PKB has yet to be demonstrated in non-transfected cells (i.e.
under conditions where the proteins are not overexpressed).
Anoikis
An additional mammalian system in which a role for PI-3K has
been implicated is in the regulation of epithelial- and endothelial-
cell apoptosis during the induction of cell death upon detachment
from matrix, a process termed ‘anoikis ’ [119]. This mechanism
normally ensures that cells do not survive outside the context of
their normal environment. In Madin–Darby canine kidney
(MDCK) cells it has been demonstrated that detachment from
the matrix leads to a rapid decrease in the levels of PI-3K
products and PKB activity, and vice versa for attachment [120].
Introduction of active mutants of p21ras, PI-3K or PKB protects
MDCK cells from apoptosis in suspension, while inhibition of
PI-3K with LY294002, or PKB by transient expression of the PH
domain alone [51], resulted in enhanced apoptosis of adhered
cells [120]. These data suggest a model whereby through en-
gagement of integrins by extracellular-matrix interactions, PI-3K
becomes activated and provides a protective signal through
activation of PKB. Epithelial-cell detachment results in PI-3K,
and thus PKB, inhibition and the apoptotic pathway is triggered.
Most importantly, the activation of p21ras by oncogenic mu-
tation, results in the activation of PI-3K in epithelial cells in
suspension and thus overrides the normal death signal. These
data provide an explanation for how transformed cells are able
to grow in the absence of contact with the extracellular matrix
and demonstrate a critical role for PKB. The fact that PKB has
been found overexpressed in a variety of human tumours may
well be due to the fact that it can promote survival of transformed
cells under conditions where normally apoptosis would prevent
malignant growth.
Transformation
As discussed above, PKB was initially identified as the cellular
counterpart of the v-akt oncogene and has been found over-
expressed in various tumours. The mechanisms by which PKB
can transform cells are, however, not clear, although several
recent studies have provided the first clues to its transforming
potential. Recent data have demonstrated that transfection of
NIH 3T3 cells with gag–PKB was insufficient to transform cells.
Active Ras mutants capable of activating the Raf}ERK pathway,
but incapable of activating PI-3K (Ras V12 E38), were also
transformation incompetent [121]. However, co-transfection of
these constructs results in a synergistic transformation capability,
suggesting that although PKB by itself is a very weak oncogene,
it can provide a transforming signal which complements that of
the Raf pathway.
The breakpoint cluster region–Abelson (BCR}ABL) onco-
genic tyrosine kinase plays an essential role in the pathogenesis
of chronicmyelogenous leukemia andPhiladelphia acute lympho-
blastic leukaemia. This kinase activates PI-3K by a mechanism
requiring the binding of BCR}ABL to the p85 subunit of PI-3K
[122]. Pharmacological inhibition of PI-3K suppresses BCR}
ABL-dependent colony formation of murine bone-marrow cells,
suggesting a critical role for this pathway in mediating the
oncogenic capacity of BCR}ABL. This effect appears to be
mediated by PKB, since a kinase-dead PKB mutant inhibited
BCR}ABL-dependent transformation of murine bone-marrow
cells in itro and suppressed leukaemia development in severe-
combined-immunodeficiency (SCID) mice. Furthermore, a mu-
tant of PKB that has been said to be constitutively active (E40K;
[33]) markedly enhanced growth-factor-independent colony
formation and leukaemia in SCID mice infected with trans-
formation-defective BCR}ABL mutants. PKB was further found
to activate c-Myc and Bcl-2 expression in murine bone-marrow
cells, suggesting that the mechanisms by which PKB induces
transformation is tightly linked with its ability to regulate
apoptosis. These studies demonstrate an essential role for PKB
in BCR}ABL leukaemogenesis.
Interestingly, recent analysis of the avian sarcoma virus 16
(AV16) genome has revealed that it encodes an oncogene derived
from the cellular gene for the catalytic subunit of PI-3K [123].
AV16 induces haemangiosarcomas in chickens and transforms
cultured chicken embryo fibroblasts (CEFs). The viral gene,
named v-p3k, is a fusion between its cellular counterpart, c-p3k
and the viral gag gene. This is, of course, reminiscent of the PKB
and gag fusion that is found in v-akt [11]. CEFs transformed
with either v-p3k or c-p3k showed elevated levels of both
PtdIns(3,4)P
#
and PtdIns(3,4,5)P
$
as well as enhanced activation
of PKB. Thus, as is observed in the p21ras-ERK signalling
pathway, several components of the PI-3K signalling pathway
have now also been identified as transforming oncogenes.
Genetic analysis of the PKB pathway
Activation of regulatory survival mechanisms are thought to be
critical in embryonic development and longevity of adult tissues.
Indeed a C. elegans PI-3K homologue has recently been impli-
cated in mediating longevity [124]. Analysis of the role of C.
elegans PKB homologues will shed light on whether this kinase
mediates these survival effects [14]. A Drosophila homologue of
PKB was identified by two groups [15,23]. Recently a mutation
in the Drosophila gene was isolated which has shed light on the
physiological functions of the protein kinase during development
[125]. The mutation consists of a single amino acid change in the
highly conserved DFG motif in subdomain VII and results in
substitution of isoleucine for phenylalanine. This completely
inactivates the protein kinase (introduction of an analogous
mutation in mammalian PKB has a similar effect), but does not
alter protein expression nor phosphorylation at the activation
sites (in the case of the Drosophila PKB, T342 and S505; Figure
1). The mutation can be efficiently rescued by transgenic ex-
pression of wild-type Drosophila PKB and to a lesser, but
significant, extent by bovine PKB. The inactive protein therefore
does not encode a transdominant negative mutant (consistent
with the intermolecular-regulation model ; see under ‘PKB
complexes’ above).
Loss of PKB function in fruitflies results in embryonic lethality
[124]. The gene is maternally expressed (i.e. RNA from the
mother is deposited into the egg during oogenesis and directs
synthesis of the protein during the early stages of development
until zygotic transcription is initiated following nucleation).
Germ-line clone analysis demonstrated that, in the absence of
zygotic transcription of PKB, there was a severe defect in cuticle
formation. This effect is similar to deregulated apoptosis [126].
Further analysis showed that the mutant embryos exhibited
ectopic apoptosis, as judged by Acridine Orange staining, which
preferentially stains blebbing membranes, and terminal de-
oxynucleotidyltransferase-mediated dUTP nick-end-labelling
(TUNEL) assays (which detects DNA ends). The phenotype
could be suppressed by expression of baculoviral P35, an inhibitor
of caspase activation, indicating the effect is not simply a
consequence of abrogated development [125]. Expression of a
dominant interfering mutant of the catalytic subunit of PI-3K
phenocopied the effect of the PKB mutation, indicating that
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PI-3K signalling acts via PKB to repress apoptosis in flies, a
similar situation to that occuring in mammals (A. Manoukian,
B. Staveley, L. Ruel, J. Jin and J. R. Woodgett, unpublished
work; see above).
TUNEL staining of normal embryos reveals that a small
fraction of cells naturally die by apoptosis. Indeed, studies of
cell-death regulatory genes (such as ced9 and ced4 in C. elegans)
have previously demonstrated the occurrence of controlled cell
death during development [127,128]. Expression of activated
mutants of PKB in Drosophila inhibits this normal death but
does not interfere with viability (J. Jin, L. Ruel, B. Staveley,
A. Manoukian and J. Woodgett, unpublished work). Together
these data indicate that activation of PKB via the PI-3K pathway
modulates cell death. Since essentially all of the cells in a PKB
mutant embryo undergo apoptosis, PI-3K signalling appears to
be necessary to actively repress cell death in cycling cells. This
would provide a failsafe mechanism to ensure that incomplete
mitogenic signalling does not result in viable cells. The repression
of normal cell death by activation of the PI-3K}PKB pathway
suggests that this signalling system can veto death under certain
circumstances and implies that death may be induced by selective
repression of the pathway. The mechanism by which this occurs
is, as yet, unknown.
CONCLUSIONS
Clearly there has been rapid progress in elucidating the biological
regulation and functions of PKB}c-Akt. While the kinase was
first cloned in 1991, most of the work describing the enzyme has
been published since 1997. This explosive growth in the field is
due in large part to the established research on PI-3K and the
finding that PKB was activated by PI-3K signalling. As a
consequence, much effort has been focused on understanding the
role of PKB in providing effector functions for the lipid kinase.
Many questions remain, including the relationship between
the roles of PKB in cell death and intermediate metabolism. The
advent of improved tools to dissect the function of the protein
kinase, as well as genetic analysis in simpler organisms, should
shed light on the relevant upstream and downstream components
and the relative importance of its functions in different tissues
and stages. Most importantly, the next wave of research should
determine the therapeutic promise of modulation of the PKB
pathway. For example, tumour cells may exhibit selective sen-
sitivity to inhibition of PKB. The protein kinase is potentially a
more selective target than PI-3K, since the latter class of proteins
clearly play important roles in other cellular processes such as
vesicle fusion. On the other hand, if PKB signalling is important
for insulin action, antagonists may cause complications in blood
sugar homoeostasis. Despite the remarkable progress of recent
years, there is much to be discovered about PKB biology, and its
established role in regulating metabolism and apoptosis ensures
this field will continue to flourish.
Note added in proof (received 24 August 1998)
Integrin-linked kinase (ILK) has recently been shown to phos-
phorylate PKB at serine-473 [129]. Since ILK activity is
dependent on PI-3K activation, this protein kinase may represent
PDK2 [129].
J.R.W. is an International Scholar of the Howard Hughes Medical Institute and MRC
(Canada) Senior Scientist supported by grants from the MRC and National Cancer
Institute of Canada. P. J.C. is supported by a grant from Glaxo Wellcome b.v.
REFERENCES
1 Staal, S. P., Hartley, J. W. and Rowe, W. P. (1977) Proc. Natl. Acad. Sci. U.S.A. 74,
3065–3067
2 Staal, S. P. and Hartley, J. W. (1988) J. Exp. Med. 167, 1259–1264
3 Staal, S. P. (1987) Proc. Natl. Acad. Sci. U.S.A. 84, 5034–5037
4 Staal, S. P., Huebner, K., Croce, C. M., Parsa, N. Z. and Testa, J. R. (1988)
Genomics 2, 96–98
5 Bertness, V. L., Felix, C. A., McBride, O. W., Morgan, R., Smith, S. D., Sandberg,
A. A. and Kirsch, I. R.(1990) Cancer Genet. Cytogenet. 44, 47–54
6 Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C.,
Tsichlis, P. N. and Testa, J. R. (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 9267–9271
7 Miwa, W., Yasuda, J., Murakami, Y., Yashima, K., Sugano, K., Sekine, T., Kono, A.,
Egawa, S., Yamaguchi, K., Hayashizaki, Y. and Sekiya, T. (1996) Biochem. Biophys.
Res. Commun. 225, 968–974
8 Bellacosa, A., de Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A.,
Wan, M., Dubeau, L., Scambia, G., Masciullo, V. et al. (1995) Int. J. Cancer 64,
280–285
9 Coffer, P. J. and Woodgett, J. R. (1991) Eur. J. Biochem. 201, 475–481
10 Jones, P. F., Jakubowicz, T., Pitossi, F. J., Mauer, F. and Hemmings, B. A. (1991)
Proc. Natl. Acad. Sci. U.S.A. 88, 4171–4175
11 Bellacosa, A, Testa, J. R., Staal, S. P. and Tsichlis, P. N. (1991) Science 254,
274–277
12 Downward, J. (1995) Nature (London) 376, 553–554
13 Konishi, H., Kuroda, S., Tanaka, M., Matsuzaki, H., Ono, Y., Kameyama, K., Haga, T.
and Kikkawa, U. (1995) Biochem. Biophys. Res. Commun. 216, 526–534
14 Waterston, R., Martin, C., Craxton, M., Huynh, C., Coulson, A., Hillier, L., Durbin, R.,
Green, P., Shownkeen, R., Halloran, N. et al. (1992) Nature Genet. 1, 114–123
15 Franke, T. F., Tartof, K. D. and Tsichlis, P. N. (1994) Oncogene 9, 141–148
16 Ahmed, N. N., Franke, T. F., Bellacosa, A., Datta, K., Maria-Eugunia, G. P., Taguchi,
T., Testa, J. R. and Tsichlis, P. N. (1993) Oncogene 8, 1957–1963
17 Haslam, R. J., Koide, H. B. and Hemmings, B. A. (1993) Nature (London) 363,
309–310
18 Mayer, B. J., Ren, R., Clark, K. L. and Baltimore, D. (1993) Cell 73, 629–630
19 Bellacosa, A., Franke, T. F., Gonzalez-Portal, M. E., Datta, K., Taguchi, T., Gardner, J.,
Cheng, J. Q., Testa, J. R. and Tsichlis, P. N. (1993) Oncogene 8, 745–754
20 Altomare, D.A, Guo, K., Cheng, J. Q., Sonoda, G., Walsh, K. and Testa, J. R. (1995)
Oncogene 11, 1055–1060
21 Kohn, A. D., Summers, S. A., Birnbaum, M. J. and Roth, R. A. (1996) J. Biol. Chem.
271, 31372–31378
22 Magun, R., Burgering, B. M., Coffer, P. J., Pardasani, D., Lin, Y., Chabot, J. and
Sorisky, A. (1996) Endocrinology (Baltimore) 137, 3590–3593
23 Andjelkovic, M., Jones, P. F., Grossniklaus, U., Cron, P., Schier, A. F., Dick, M.,
Bilbe, G. and Hemmings, B. A. (1995) J. Biol. Chem. 270, 4066–4075
24 Burgering, B. M. and Coffer, P. J. (1995) Nature (London) 376, 599–602
25 Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K.,
Kaplan, D. R. and Tsichlis, P. N. (1995) Cell 81, 727–736
26 Kohn, A. D., Kovacina, K. S. and Roth, R. A. (1995) EMBO J. 14, 4288–4295
27 Kohn, A. D., Takeuchi, F. and Roth, R. A. (1996) J. Biol. Chem. 271, 21920–21926
28 Heldin, C. H. (1995) Cell 80, 213–223
29 Hara, K., Yonezawa, K., Sakaue, H., Kotani, K., Kotani, K., Kojima, A., Waterfield,
M. D. and Kasuga, M. (1995) Biochem. Biophys. Res. Commun. 208, 735–741
30 Didichenko, S. A., Tilton, B., Hemmings, B. A., Ballmer-Hofer, K. and Thelen, M.
(1996) Curr. Biol. 6, 1271–1278
31 Klippel, A., Reinhard, C., Kavanaugh, M. W., Apell, G., Escobedo, M. A. and Williams,
L. T. (1996) Mol. Cell. Biol. 16, 4117–4127
32 Konishi, H., Matsuzaki, H., Tanaka, M., Ono, Y., Tokunaga, C., Kuroda, S. and
Kikkawa, U. (1996) Proc. Natl. Acad. Sci. U.S.A. 93, 7639–7643
33 Ahmed, N. N., Grimes, H. L., Bellacosa, A., Chan, T. O. and Tsichlis, P. N. (1997)
Proc. Natl. Acad. Sci. U.S.A. 94, 3627–3632
34 King, W. G., Mattaliano, M. D., Chan, T. O., Tsichlis, P. N. and Brugge, J. S. (1997)
Mol. Cell. Biol. 17, 4406–4418
35 Mazure, N. M., Chen, E..Y., Laderoute, K. R. and Giaccia, A. J. (1997) Blood 90,
3322–3331
36 Reif, K., Burgering, B. M. and Cantrell, D. A. (1997) J. Biol. Chem. 272,
14426–14433
37 Songyang, Z., Baltimore, D., Cantley, L. C., Kaplan, D. R. and Franke, T. F. (1997)
Proc. Natl. Acad. Sci. U.S.A. 94, 11345–11350
38 Tilton, B., Andjelkovic, M., Didichenko, S. A., Hemmings, B. A. and Thelen, M. (1997)
J. Biol. Chem. 272, 28096–28101
39 Coffer, P. J., Schweizer, R. C., Dubois, G. R., Maikoe, T., Lammers, J-W. J. and
Koenderman, L. (1998) Blood 91, 2547–2557
40 Andjelkovic, M., Suidan, H. S., Meier, R., Frech, M., Alessi, D. R. and Hemmings,
B. A. (1998) Eur. J. Biochem. 251, 195–200
12 P. J. Coffer, J. Jin and J. R. Woodgett
41 Sable, C. L., Filippa, N., Hemmings, B. and Van Obberghen, E. (1997) FEBS Lett.
409, 253–257
42 Moule, S. K., Welsh, G. I., Edgell, N. J., Foulstone, E. J., Proud, C. G. and Denton,
R. M. (1997) J. Biol. Chem. 272, 7713–7719
43 Zundel, W. and Giaccia, A. (1998) Genes Dev. 12, 1941–1946
44 Zhou, H., Summers, S. A., Birnbaum, M. J. and Pittman, R. N. (1998) J. Biol. Chem.
273, 16568–16575
45 Klippel, A., Kavanaugh, W. M., Pot, D. and Williams, L. T. (1997) Mol. Cell. Biol. 17,
338–344
46 Franke, T. F., Kaplan, D. R., Cantley, L. C. and Toker, A. (1997) Science 275,
665–668
47 James, S. R., Downes, C. P., Gigg, R., Grove, S. J., Holmes, A. B. and Alessi, D. R.
(1996) Biochem. J. 315, 709–713
48 Takeuchi, H., Kanematsu, T., Misumi, Y., Sakane, F., Konishi, H., Kikkawa, U.,
Watanabe, Y., Katan, M. and Hirata, M. (1997) Biochim. Biophys. Acta 1359,
275–285
49 Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P. and
Hemmings, B. A. (1996) EMBO J. 15, 6541–6551
50 Walker, K. S., Deak, M., Paterson, A., Hudson, K., Cohen, P. and Alessi, D. R. (1998)
Biochem. J. 331, 299–308
51 Datta, K., Franke, T. F., Chan, T. O., Makris, A., Yang, S. I., Kaplan, D. R., Morrison,
D. K., Golemis, E. A. and Tsichlis, P. N. (1995) Mol. Cell. Biol. 15, 2304–2310
52 Yao, R. and Cooper, G. M. (1995) Science 267, 2003–2006
53 Konishi, H., Shinomura, T., Kuroda, S., Ono, Y. and Kikkawa, U. (1994) Biochem.
Biophys. Res. Commun. 205, 817–825
54 Konishi, H., Kuroda, S. and Kikkawa, U. (1994) Biochem. Biophys. Res. Commun.
205, 1770–1775
55 Reference deleted
56 Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, C. B.
and Cohen, P. (1997) Curr. Biol. 7, 261–269
57 Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R., Reese, C. B., Painter, G. F.,
Holmes, A. B., McCormick, F. and Hawkins, P. T. (1997) Science 277, 567–570
58 Alessi, D. R., Deak, M., Casamayor, A., Caudwell, F. B., Morrice, N., Norman, D. G.,
Gaffney, P., Reese, C. B., MacDougall, C. N., Harbison, D. et al. (1997) Curr. Biol. 7,
776–789
59 Stephens, L., Anderson, K., Stokoe, D., Erdjument-Bromage, H., Painter, G. F.,
Holmes, A. B., Gaffney, P. R., Reese, C. B., McCormick, F., Tempst, P. et al. (1998)
Science 279, 710–714
60 Anderson, K. E., Coadwell, J., Stephens, L. R. and Hawkins, P. T. (1998) Curr. Biol.
8, 684–691
61 Andjelkovic, M., Alessi, D. R., Meier, R., Fernandez, A., Lamb, N. J., Frech, M., Cron,
P., Cohen, P., Lucocq, J. M. and Hemmings, B. A. (1997) J. Biol. Chem. 272,
31515–31524
62 Meier, R., Alessi, D. R., Cron, P., Andjelkovic, M. and Hemmings, B. A. (1997)
J. Biol. Chem. 272, 30491–30497
63 van Weeren, P. C., de Bruyn, K. M., de Vries-Smits, A. M., van Lint, J. and
Burgering, B. M. (1998) J. Biol. Chem. 273, 13150–13156
64 Cheatham, B., Vlabos, C. J., Cheatham, L., Wang, B. J. and Kahn, C. R. (1994)
Mol. Cell Biol. 14, 4902–4911
65 Okada, T., Kawano, Y., Sakakibara, T., Hazeki, O. and Ui, M. (1994) J. Biol. Chem.
269, 3568–3573
66 Quon, M. J., Chen, H., Ing, B. L., Liu, M. L., Zarnowski, M. J., Yonezawa, K., Kasuga,
M., Cushman, S. W. and Taylor, S. I. (1995) Mol. Cell. Biol. 15, 5403–5411
67 Katagiri, H., Asano, T., Ishihara, H., Inukai, K., Shibasaki, Y., Kikuchi, M., Yazaki, Y.
and Oka, Y. (1996) J. Biol. Chem. 271, 16987–16990
68 Martin, S. S., Haruta, T., Morris, A. J., Klippel, A., Williams, L. T. and Olefsky, J. M.
(1996) J. Biol. Chem. 271, 17605–17608
69 Tanti, J. F., Gremeaux, T., Grillo, S., Calleja, V., Klippel, A., Williams, L. T., Van
Obberghen, E. and Le Marchand-Brustel, Y. (1996) J. Biol. Chem. 271,
25227–25232
70 Frevert, E. U. and Kahn, B. B. (1997) Mol. Cell. Biol. 17, 190–198
71 Tanti, J. F., Grillo, S., Gremeaux, T., Coffer, P. J., Van Obberghen, E. and Le
Marchand-Brustel, Y. (1997) Endocrinology (Baltimore) 138, 2005–2010
72 Hajduch, E., Alessi, D. R., Hemmings, B. A. and Hundal, H. S. (1998) Diabetes 47,
1006–1013
73 Yeh, W. C., Bierer, B. E. and McKnight, S. L. (1995) Proc. Natl. Acad. Sci. U.S.A. 92,
11086–90
74 Gould, G. W., Jess, T. J., Andrews, G. C., Herbst, J. J., Plevin, R. J. and Gibbs, E. M.
(1994) J. Biol. Chem. 269, 26622–26625
75 Ricort, J. M., Tanti, J. F., Van Obberghen, E. and Le Marchand-Brustel, Y. (1996)
Eur. J. Biochem. 239, 17–22
76 Nave, B. T., Haigh, R. J., Hayward, A. C., Siddle, K. and Shepherd, P. R. (1996)
Biochem. J. 318, 55–60
77 Calera, M. R., Martinez, C., Liu, H., El Jack, A. K., Birnbaum, M. J. and Pilch, P. F.
(1998) J. Biol. Chem. 273, 7201–7204.
78 Cohen, P., Parker, P. J. and Woodgett, J. R. (1985) in Molecular Basis of Insulin
Action (Czech, M. P., ed.), pp. 213–233, Plenum Press, New York
79 Woodgett, J. R. (1994) Semin. Cancer Biol. 5, 269–275
80 Welsh, G. I., Wilson, C. and Proud, C. G. (1996) Trends Cell Biol. 6, 274–279
81 Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M. and Hemmings, B. A.
(1995) Nature (London) 378, 785–789
82 Ueki, K., Yamamoto-Honda, R., Kaburagi, Y., Yamauchi, T., Tobe, K., Burgering,
B. M. T., Coffer, P. J., Komuro, I., Akanuma, Y., Yazaki, Y. and Kadowaki, T. (1998)
J. Biol. Chem. 273, 5315–5322
83 Benjamin, W. B., Pentyala, S. N., Woodgett, J. R., Hod, Y. and Marshak, D. (1994)
Biochem. J. 300, 477–482
84 Brady, M. J., Bourbonais, F. J. and Saltiel, A. R. (1998) J. Biol. Chem. 273,
14063–14066
85 Deprez, J., Vertommen, D., Alessi, D. R., Hue, L. and Rider, M. H. (1997) J. Biol.
Chem. 272, 17269–17275
86 Lefebvre, V., Mechin, M. C., Louckx, M. P., Rider, M. H. and Hue, L. (1996) J. Biol.
Chem. 271, 22289–22292
87 Kimball, S. R., Vary, T. C. and Jefferson, L. S. (1994) Annu. Rev. Physiol. 56,
321–348
88 Azpiazu, I., Saltiel, A. R., DePaoli-Roach, A. A. and Lawrence, J. C. (1996) J. Biol.
Chem. 271, 5033–5039
89 Beretta, L., Gingras, A. C., Svitkin, Y. V., Hall, M. N. and Sonenberg, N. (1996)
EMBO J. 15, 658–664
90 Fadden, P., Haystead, T. A. and Lawrence, J. C. (1997) J. Biol. Chem. 272,
10240–10247
91 Gingras, A. C., Kennedy, S. G., O’Leary, M. A., Sonenberg, N. and Hay, N. (1998)
Genes Dev. 12, 502–513
92 Alessi, D. R., Kozlowski, M. T., Weng, Q. P., Morrice, N. and Avruch, J. (1997)
Curr. Biol. 8, 69–81
93 Pullen, N., Dennis, P. B., Andjelkovic, M., Dufner, A., Kozma, S. C., Hemmings,
B. A. and Thomas, G. (1998) Science 279, 707–710
94 Conus, N. M., Hemmings, B. A. and Pearson, R. B. (1998) J. Biol. Chem. 273,
4776–4780
95 Barthel, A., Kohn, A. D., Luo, Y. and Roth, R. A. (1997) Endocrinology (Baltimore)
138, 3559–3562
96 Steller, H. (1995) Science 267, 1445–1449
97 Yao, R. and Cooper, G. M. (1995) Science 267, 2003–2006
98 Minshall, C., Arkins, S., Freund, G. G. and Kelley, K. W. (1996) J. Immunol. 156,
939–947
99 Scheid, M. P. and Duronio, V. (1996) J. Biol. Chem. 271, 18134–18139
100 Yao, R. and Cooper, G. M. (1996) Oncogene 13, 343–351
101 Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M.,
Segal, R. A., Kaplan, D. R. and Greenberg, M. E. (1997) Science 275, 661–665
102 Philpott, K. L., McCarthy, M. J., Klippel, A. and Rubin, L. L. (1997) J. Cell Biol.
139, 809–815
103 Eves, E. M., Xiong, W., Bellacosa, A., Kennedy, S. G., Tsichlis, P. N., Rosner, M. R.
and Hay, N. (1998) Mol. Cell. Biol. 18, 2143–2152
104 Crowder, R. J. and Freeman, R. S. (1998) J. Neurosci. 18, 2933–2943
105 Harrington, E. A., Bennett, M. R., Fanidi, A. and Evan, G. I. (1994) EMBO J. 13,
3286–3295
106 Vlahos, C. J., Matter, W. F., Hui, K. Y. and Brown, R. F. (1994) J. Biol. Chem. 269,
5241–5248
107 Kauffmann-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P.,
Downward, J. and Evan, G. (1997) Nature (London) 385, 544–548
108 Kulik, G., Klippel, A. and Weber, M. J. (1997) Mol. Cell. Biol. 17, 1595–1606
109 Brennan, P., Babbage, J. W., Burgering, B. M., Groner, B., Reif, K. and Cantrell,
D. A. (1997) Immunity 7, 679–689
110 Kennedy, S. G., Wagner, A. J., Conzen, S. D., Jordan, J., Bellacosa, A., Tsichlis,
P. N. and Hay, N. (1997) Genes Dev. 11, 701–713
111 Gajewski, T. F. and Thompson, C. B. (1996) Cell 87, 589–592
112 Zha, J., Harada, H., Yang, E., Jockel, J. and Korsmeyer, S. J. (1996) Cell 87,
619–628
113 Yaffe, M. B., Rittinger, K., Volinia, S., Caron, P. R., Aitken, A., Leffers, H., Gamblin,
S. J., Smerdon, S. J. and Cantley, L. C. (1997) Cell 91, 961–971
114 Wang, H.-G., Rapp, U. R. and Reed, J. C. (1996) Cell 87, 629–638
115 Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y. and Greenberg, M. E.
(1997) Cell 91, 231–241
116 del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R. and Nunez, G. (1997)
Science 278, 687–689
117 Blume-Jensen, P., Janknecht, R. and Hunter, T. (1998) Curr. Biol. 8, 779–782
118 Scheid, M. P. and Duronio, V. (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 7439–7444
13Protein kinase B (c-Akt)
119 Frisch, S. M. and Francis, H. (1994) J. Cell Biol. 124, 619–626
120 Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H. and Downward, J.
(1997) EMBO J. 16, 2783–2793.
121 Marte, B. M., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H. and Downward, J.
(1997) Curr. Biol. 7, 63–70
122 Skorski, T., Bellacosa, A., Nieborowska-Skorska, M., Majewski, M., Martinez, R.,
Choi, J. K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T. O. et al. (1997) EMBO J.
16, 6151–6161
123 Chang, H. W., Aoki, M., Fruman, D., Auger, K. R., Bellacosa, A., Tsichlis, P. N.,
Cantley, L. C., Roberts, T. M. and Vogt, P. K. (1997) Science 276, 1848–1850
124 Morris, J. Z., Tissenbaum, H. A. and Ruvkun, G. (1996) Nature (London) 382,
536–539
125 Staveley, B. E., Laurent Ruel, L., Jin, J., Stambolic, V., Mastronardi, F. G., Heitzler,
P., Woodgett, J. R. and Manoukian, A. S. (1998) Curr. Biol. 8, 599–602
126 Chen, P., Nordstrom, W., Gish, B. and Abrams, J. M. (1996) Genes Dev. 10,
1773–1782
127 Hengartner, M. O. and Horvitz, H. R. (1994) Curr. Opin. Genet. Dev. 4, 581–586
128 Jacobson, M. D., Weil, M. and Raff, M. C. (1997) Cell 8, 347–354.
129 Delcommenne, M., Tan, C., Gray, V., Ruel, L., Woodgett, J. and Dedhar, S. (1998)
Proc. Natl. Acad. Sci. U.S.A., in the press
